Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
NCT04374149
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Cytokine Release Syndrome
COVID19
Interventions
PROCEDURE:
Therapeutic Plasma Exchange
DRUG:
Ruxolitinib
Sponsor
Prisma Health-Upstate